TANDEM DIABETES CARE INC (TNDM)
US8753722037 - Common Stock
TNDM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of TNDM have multiple concerns. TNDM is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TNDM had negative earnings in the past year.
TNDM had a negative operating cash flow in the past year.
In the past 5 years TNDM reported 4 times negative net income.
Of the past 5 years TNDM 4 years had a positive operating cash flow.
1.2 Ratios
TNDM has a Return On Assets of -15.04%. This is comparable to the rest of the industry: TNDM outperforms 57.29% of its industry peers.
The Return On Equity of TNDM (-58.22%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.04% | ||
| ROE | -58.22% | ||
| ROIC | N/A |
ROA(3y)-10.21%
ROA(5y)-8.61%
ROE(3y)-29.63%
ROE(5y)-22.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TNDM has a Gross Margin of 49.28%. This is comparable to the rest of the industry: TNDM outperforms 41.67% of its industry peers.
TNDM's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for TNDM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.99%
GM growth 5Y0.14%
2. Health
2.1 Basic Checks
TNDM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNDM has been increased compared to 1 year ago.
The number of shares outstanding for TNDM has been increased compared to 5 years ago.
TNDM has a worse debt/assets ratio than last year.
2.2 Solvency
TNDM has an Altman-Z score of 2.48. This is not the best score and indicates that TNDM is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.48, TNDM is doing good in the industry, outperforming 63.02% of the companies in the same industry.
TNDM has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.43, TNDM is not doing good in the industry: 82.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.48 |
ROIC/WACCN/A
WACC9.69%
2.3 Liquidity
TNDM has a Current Ratio of 3.81. This indicates that TNDM is financially healthy and has no problem in meeting its short term obligations.
TNDM has a Current ratio of 3.81. This is comparable to the rest of the industry: TNDM outperforms 56.25% of its industry peers.
A Quick Ratio of 3.01 indicates that TNDM has no problem at all paying its short term obligations.
TNDM has a Quick ratio (3.01) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.01 |
3. Growth
3.1 Past
TNDM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.72%, which is quite impressive.
The Revenue has decreased by -3.11% in the past year.
TNDM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.38% yearly.
EPS 1Y (TTM)31.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.19%
Revenue 1Y (TTM)-3.11%
Revenue growth 3Y14.45%
Revenue growth 5Y32.38%
Sales Q2Q%13.16%
3.2 Future
TNDM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.48% yearly.
The Revenue is expected to grow by 9.84% on average over the next years. This is quite good.
EPS Next Y46.32%
EPS Next 2Y28.07%
EPS Next 3Y20.78%
EPS Next 5Y13.48%
Revenue Next Year13.9%
Revenue Next 2Y12.67%
Revenue Next 3Y11.95%
Revenue Next 5Y9.84%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
TNDM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TNDM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TNDM's earnings are expected to grow with 20.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.07%
EPS Next 3Y20.78%
5. Dividend
5.1 Amount
No dividends for TNDM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TANDEM DIABETES CARE INC
NASDAQ:TNDM (5/31/2024, 7:09:41 PM)
After market: 51.23 0 (0%)51.23
-2.2 (-4.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.31B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.04% | ||
| ROE | -58.22% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.28% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)31.72%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y46.32%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-3.11%
Revenue growth 3Y14.45%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y